IGFBP3 and type 2 diabetes mellitus: The increased hepatic production of IGFBP3 observed in vitro upon exposure to either T1D or T2D serum and the abrogation obtained by targeting the pro-inflammatory microenvironment further suggest a common path of dysregulation for the IGFBP3/TMEM219 axis in diabetes.